Healthcare Professionals

Virtual Conference on Alpha Thalassaemia Major By UCSF on 8-9 January 2021
News

Virtual Conference on Alpha Thalassaemia Major By UCSF on 8-9 January 2021

The Center for Maternal-Fetal Precision Medicine (UCSF) will host a 2-day online international conference on Alpha Thalassaemia Major, which was once considered universally fatal in utero, on 8-9 January 2021. …
PK Deficiency Resources Now Available On TIF’s Website
News

PK Deficiency Resources Now Available On TIF’s Website

Recognizing the similarities of thalassaemia with other rare anaemias, particularly those affecting red blood cells, (e.g. PKD, SCD), and noting the absence of disease-specific united internationally coordinated patient organizations to…
What’s New In Clinical Trials for Thalassaemia and Sickle Cell Disease?
Clinical News

What’s New In Clinical Trials for Thalassaemia and Sickle Cell Disease?

There is a lot of hustle and bustle in the scientific fields of thalassemia and sickle cell disease during the past few months, with many companies making remarkable progress in…
EU Approves Adakveo to Treat Vaso Occlusive Crises in Sickle Cell Disease Patients
Clinical News

EU Approves Adakveo to Treat Vaso Occlusive Crises in Sickle Cell Disease Patients

The European Commission has approved Novartis’ Adakveo (crizanlizumab) as a preventive treatment for recurrent Vaso-Occlusive Crises (VOCs) in patients, 16 and older, with sickle cell disease (SCD). This approval follows a recommendation for conditional approval issued in July…
eThalED Webinar Series: Current Standard Care & New Advances in Iron Chelation
eThalED Webinars

eThalED Webinar Series: Current Standard Care & New Advances in Iron Chelation

TIF´s last webinar for the eThalED series for Medical Specialists on October 16, 2020, featured Dr Farrukh Shah, Consultant Haematologist, Whittington Hospital, London, UK, who reviewed all the current practices…
Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease
Clinical News

Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease

Fulcrum Therapeutics, Inc.  a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that FTX-6058, its investigational treatment for sickle cell disease (SCD) and…
Gene-editing Therapy CTX-001 Granted Priority Medicines Designation for Severe SCD in EU
News

Gene-editing Therapy CTX-001 Granted Priority Medicines Designation for Severe SCD in EU

CTX001, an investigational gene-editing cell therapy, has been granted priority medicines (PRIME) designation by the European Medicines Agency (EMA) for the treatment of severe sickle cell disease (SCD). The announcement was made by CRISPR Therapeutics and Vertex Pharmaceuticals, which are jointly…
Coming Up: A TIF Live Webinar on “Heart Disease in Thalassaemia“
News

Coming Up: A TIF Live Webinar on “Heart Disease in Thalassaemia“

Tune in with TIF on Tuesday, 15 September 2020, 15:00 EEST, for one of the last webinars from the TIF eThalED series for Healthcare Professionals! The topic to be brought…
eThalED Webinar Series: Iron Monitoring in Thalassaemia
Education

eThalED Webinar Series: Iron Monitoring in Thalassaemia

TIF´s 5th consecutive webinar for Medical Specialists and Healthcare Professionals was conducted on 7 September 2020 and revolved around the topic of “Iron Monitoring in Thalassaemia“. Dr Paul Telfer, Consultant…
eThalED Webinar Series: Blood Transfusion in Thalassaemia
Education

eThalED Webinar Series: Blood Transfusion in Thalassaemia

TIF´s 4th Webinar for Medical Specialists and Healthcare Professionals, organised as part of our eThalED Course, was successfully held on Monday, 31 August 2020. Prof. Constantina Politis, Associate Professor of…
Schaltfläche "Zurück zum Anfang"